Targeting the oxidative activation of PKG Ialpha as a treatment for HFpEF

心力衰竭是一种常见的疾病，在英国每年导致20万人死亡。心力衰竭大致可以分为两种不同的类型，其中一种被称为心力衰竭伴保留射血分数或HFpEF。心脏是一个泵，充满血液，然后通过收缩将其泵出到身体的其他部位。每次心脏跳动的时候都会发生这种情况。对于患有HFpEF的人来说，问题是他们的心脏不能适当地放松和充血，不仅直接损害了它有效泵血的能力，而且还引发了心脏组织的其他变化，使情况进一步恶化。我们已经确定了一种在治疗HFpEF方面显示出希望的早期药物，但我们需要更多资金来使开发和评估我们正在制造的这种化合物和衍生物的工作成为可能，然后才能进行人体研究。我们认为我们的研究很重要，因为目前还没有有效治疗HFpEF患者的药物，不幸的是，这种情况继续变得更加普遍。

Heart failure is a common medical condition that causes the deaths of 200,000 people a year in the United Kingdom. Heart failure can be broadly categorised into two different type, and one them is called Heart Failure with Preserved Ejection fraction or HFpEF. The heart is a pump, filling with blood and then pumping it out to the rest of the body by contracting. This happens every time every time the heart beats. The problem for people with HFpEF is that their heart does not relax and fill with blood properly, not only directly impairing its ability to pump efficiently, but also causing triggering other changes in the heart tissue that make the situation progressively worse. We have identified an early stage drug that shows promise in the treatment of HFpEF, but we require more funds to enable work developing and evaluating this compound and derivatives we are making before studies in humans are possible. We think our studies are important as there are no drugs at this time that are effective in the treatment of HFpEF patients and unfortunately, this condition continues to become more prevalent.